Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | OLMA | Common Stock, par value $0.0001 per share | Sale | -$27.9M | -1.87M | -28.38% | $14.92 | 4.72M | Aug 1, 2024 | By: Paradigm BioCapital International Fund Ltd. | F1 |
transaction | OLMA | Common Stock, par value $0.0001 per share | Sale | -$7.9M | -530K | -40.34% | $14.92 | 783K | Aug 1, 2024 | By: One or more separately managed accounts | F2 |
Paradigm Biocapital Advisors LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Id | Content |
---|---|
F1 | These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose. |
F2 | These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose. |